Financial giants have made a conspicuous bearish move on Novavax. Our analysis of options history for Novavax NVAX revealed 12 unusual trades.
Delving into the details, we found 41% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $149,921, and 7 were calls, valued at $550,394.
Projected Price Targets
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $5.5 and $25.0 for Novavax, spanning the last three months.
Volume & Open Interest Development
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novavax's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novavax's substantial trades, within a strike price spectrum from $5.5 to $25.0 over the preceding 30 days.
Novavax 30-Day Option Volume & Interest Snapshot
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVAX | CALL | SWEEP | BEARISH | 01/16/26 | $5.7 | $4.95 | $4.95 | $25.00 | $229.9K | 226 | 368 |
| NVAX | CALL | SWEEP | BEARISH | 01/16/26 | $5.7 | $4.9 | $4.9 | $25.00 | $98.0K | 226 | 837 |
| NVAX | CALL | SWEEP | BEARISH | 07/05/24 | $3.9 | $3.75 | $3.75 | $15.00 | $75.0K | 73 | 0 |
| NVAX | CALL | SWEEP | BULLISH | 09/20/24 | $3.15 | $2.93 | $3.15 | $20.00 | $47.2K | 1.1K | 162 |
| NVAX | CALL | TRADE | BEARISH | 01/16/26 | $6.65 | $4.65 | $5.0 | $25.00 | $38.5K | 226 | 164 |
About Novavax
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
In light of the recent options history for Novavax, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Current Position of Novavax
- With a volume of 5,278,270, the price of NVAX is down -2.2% at $17.82.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 63 days.
Expert Opinions on Novavax
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $17.5.
- An analyst from TD Cowen has decided to maintain their Hold rating on Novavax, which currently sits at a price target of $10.
- An analyst from B of A Securities upgraded its action to Neutral with a price target of $12.
- An analyst from B. Riley Securities persists with their Buy rating on Novavax, maintaining a target price of $29.
- In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $19.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Novavax, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
